InvestorsKeyhole Upgrades & Downgrades

Exact Sciences (EXAS) Stock Upgraded to Buy

Analysts at Goldman Sachs raised their rating on shares of Exact Sciences (EXAS) stock from “Neutral” to “Buy” on Tuesday.

Already a member?

Login to see your Upgrades And Downgrades Trade Idea.

Not yet a member?

You can receive four timely bull-put credit spreads each market day by joining our InvestorsKeyhole Daily Trade Alerts Service. Our analysts scour the news looking for unusual options activity, how insiders are trading, and breaking news, and publish trades accordingly.

Become A Member

EXAS
About Exact Sciences Corporation

Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of certain types of cancer. Its core product is a noninvasive screening test, Cologuard, which analyzes stool-based DNA samples to detect the precancerous and early stages of colorectal cancer. The test includes DNA markers and a protein marker that can detect blood in the stool. Exact Sciences receives revenue from two sources: laboratory services and licensing fees. Its laboratory services revenue is generated by diagnostic services that use the Cologuard test. Exact Sciences also receives revenue from the licensing of its product rights.

  • Last Price:
    $115.99
  • Previous Close:
    $115.70
  • Change:
    $0.29 (0.25%)
  • Open:
    $116.22
  • Volume:
    1,344,917
  • Average Volume (100 Day):
    1,757,252
  • Market Capitalization:
    $15.0 B
  • Day's Range:
    $115.16 - $117.74
  • Dividend Yield:
    0.00%
  • 52-week Range:
    $117 - $47.78
  • P-E:
    0.00
  • EPS:
    $-1.77
  • Earnings Date:
    8/7/19
  • Ex Dividend Date:
    N/A
  • Sector:
    Healthcare
  • Industry:
    Diagnostics & Research
  • Analyst Average Recommendation:
    Strong Buy

Download this step-by-step guide on placing InvestorsKeyhole Daily Trade Alerts.

How to place a credit spread

How to place a vertical debit spread

|

You May Also Like